A phase I/II clinical study on second-generation HER2-CAR-T cell therapy in patients with recurrent/refractory HER2-positive sarcoma reported no significant toxic side effects when the infusion cell volume reached 1×108/m2. The gene discussed is ERBB2; the disease is sarcoma.